Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference49 articles.
1. A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC);Al-Batran;J. Clin. Oncol.,2017
2. Second-line treatments for advanced gastric cancer: interpreting outcomes by network meta-analysis;Badiani;World J. Clin. Oncol.,2015
3. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric Cancer;Bang;J. Clin. Oncol.,2015
4. Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300;Bang;Ann. Oncol.,2018
5. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial;Bang;Lancet Oncol.,2017
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunotherapy or targeted therapy versus best supportive care for advanced gastric cancer: a systematic review and meta-analysis of randomized trials;2024-07-15
2. Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta‐analysis;Journal of Clinical Pharmacy and Therapeutics;2021-11-18
3. A Bayesian network meta-analysis on systemic therapy for previously treated gastric cancer;Critical Reviews in Oncology/Hematology;2021-11
4. CircHAS2 promotes the proliferation, migration, and invasion of gastric cancer cells by regulating PPM1E mediated by hsa-miR-944;Cell Death & Disease;2021-09-23
5. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis;European Journal of Cancer;2021-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3